SinuSys Corp. received FDA clearance in December 2013 for its Vent-Os Sinus Dilation System, a novel in-office treatment for patients with chronic rhinosinusitis (CRS) affecting the maxillary sinus that uses a self-expanding, removable capsule and osmotic technology to open the sinuses. According to the company, the Vent-Os offers a “more with less” alternative to existing treatment modalities for millions of patients who suffer from CRS.
The magnitude of CRS is staggering. It affects one in seven adults in the US, according to the 2007 American Academy of Otolaryngology–Head and Neck Surgery Foundation’s “Clinical practice guideline: Adult sinusitis
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?